Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Helsinn
Biotech
BridgeBio, Helsinn expand collaboration to cover cancer assets
The partners have decided to work together on more prospects, starting with a potentially first-in-class cancer candidate.
Nick Paul Taylor
Nov 19, 2021 7:45am
3B Future Health launches 2nd fund for early-stage biotechs
Mar 24, 2021 9:00am
MEI Pharma, Helsinn Group cut losses on pracinostat in AML
Jul 2, 2020 9:05am
Boehringer powers cancer vaccine startup Amal to B round
Nov 12, 2018 8:07am
Helsinn gives up on Zealand’s GI candidate elsiglutide after trial flop
Jun 12, 2017 6:56am
Helsinn creates $50M VC fund to back early-stage cancer companies
Oct 10, 2016 2:00am
